Objective: The optimal therapy to achieve higher rates of survival in pediatric relapsed/refractory acute leukemia (AL) is still unknown. In developing countries, it is difficult to obtain some of the recent drugs for op...
To the Editor,
Since its approval in 1997 by the US Food and Drug Administration, use of rituximab (MabThera®, Roche,Switzerland) has become widespread, especially for the treatment of non-Hodgkin lymphoma (NHL) and chr...
EP ID EP163425
DOI 10.4274/tjh.2014.0393
Views 83
Downloads 0
How To Cite
Şinasi Özsoylu (2015). Chediak-Higashi, Hemoglobin Lansing ve Hemoglobin Jabalpur Hakkında. Turkish Journal of Hematology, 32(1),
90-91. https://europub.co.uk/articles/-A-163425
Sign In Europub
For faster login or register use your social account.
FLAG Regimen with or without Idarubicin in Children with Relapsed/Refractory Acute Leukemia: Experience from a Turkish Pediatric Hematology Center
Objective: The optimal therapy to achieve higher rates of survival in pediatric relapsed/refractory acute leukemia (AL) is still unknown. In developing countries, it is difficult to obtain some of the recent drugs for op...
Subcutaneous Myeloma Deposit in the Region of an Arteriovenous Fistula
Subcutaneous Myeloma Deposit in the Region of an Arteriovenous Fistula
F-18 [18F]-2-Fluoro-Deoxy-D-Glucose Positron Emisyon Tomografi / Bilgisayarlı Tomografi’de Primer Plevral Diffüz Büyük B Hücreli Non Hodking’s Lenfoma
Acquired Hemophilia
Rituximab-Related Reversible Hepatocellular Damage
To the Editor, Since its approval in 1997 by the US Food and Drug Administration, use of rituximab (MabThera®, Roche,Switzerland) has become widespread, especially for the treatment of non-Hodgkin lymphoma (NHL) and chr...